Aktienanalyse zu Envista Holdings Corp (NVST)NVSTEnvista Holdings Corp

Envista Holdings Corporation provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a provider of a range of solutions to support dental implants, orthodontic treatments, dental diagnostics, general dental consumable products, equipment and services. Its segments include Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. The Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems. It operates in the Healthcare sector (DENTAL EQUIPMENT & SUPPLIES industry).

Currently, Envista Holdings Corp (NVST) is priced at $22.90, which is below the analyst consensus target of $31.32, indicating potential upside. However, the RSI is at 43.78, suggesting it is nearing oversold territory, and the forward P/E ratio is 16.81, which is reasonable compared to the sector. The main risk is the recent downgrades from Piper Sandler and BMO Capital, both lowering their price targets to $26, which could indicate potential headwinds in the near term.